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Abstract
A blood test that can detect human malignancy with high clinical sensitivity and specificity is highly desirable. To
achieve this, a tumor marker is needed that correlates with tumor burden and that can be measured with high
analytical sensitivity and specificity. Over the past decades, a number of different types of tumor markers have
emerged, including proteins such as enzymes, glycoproteins, and oncofetal antigens. Besides proteins, genetic
abnormalities such as mutations, amplifications, and circulating tumor DNA have served as tumor markers. Despite
the diversity of such biomarkers, their acceptance and implementation into routine clinical practice requires that
their use results in improvements in patient outcome. Current tumor markers used in the clinic have limited utility.
As such, innovative approaches to identifying tumor markers are highly desirable and one such approach may be
to look for sub-chromosomal changes in the blood of patients with ovarian cancer, as is routinely performed in
prenatal screening.
Please see related article: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0667-6
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Background
Ovarian cancer is highly lethal. Current efforts to com-
bat this disease include improved therapies and early
diagnosis. Although it is known that detection of early
disease can lead to prolonged survival, and even cures,
most ovarian cancers are diagnosed at an advanced
stage, when surgery and chemotherapy are not very ef-
fective [1]. Subsequently, new methods for early diagno-
sis of this cancer are highly desirable.
In an article recently published in BMC Medicine,
Cohen and colleagues propose a new technique for
early ovarian cancer diagnosis, using a routine non-
invasive prenatal testing (NIPT) platform [2]. Before we
analyze this paper in some detail, we summarize below
some prerequisites that should be taken into account
when considering ovarian cancer screening.
Ovarian cancer screening is considered for women
50–75 years of age. In this age group, the prevalence of
the disease is approximately 1 in 200 women [3]. It has
previously been suggested that a screening method for
ovarian cancer should have a positive predictive value of
at least 10 % to be viable. Assuming that a test for ovar-
ian cancer screening has a sensitivity of 90 %, thus de-
tecting most early ovarian cancers, a specificity of 90 %
will yield a positive predictive value of around 4 %, and a
specificity of 95 % will yield a positive predictive value of
8 %. Consequently, the relatively low prevalence of ovar-
ian cancer in the screening population dictates that very
high specificity (i.e., > 95 %) is required to yield a viable
positive predictive value.
In the largest randomized ovarian cancer screening
trial in the UK (UK Collaborative Trial of Ovarian
Cancer Screening, UKCTOCS), three groups of women
were included: one was based on annual multimodal
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screening with serum CA125 interpreted using the risk
of ovarian cancer algorithm and transvaginal ultrasound
(multimodal screening; MMS), the second group was
based on annual transvaginal ultrasound alone (ultra-
sound screening; USS) and the third group received no
screening. The study was powered to detect a mortality
reduction of 30 %. After 11 years of follow-up, the risk
of dying from ovarian cancer was slightly reduced in the
MSS screening arm (by about 15–20 %) [3]. These data
suggest that the reduction of mortality from ovarian can-
cer with the available screening methodologies is mod-
est. Thus, the issue of screening for ovarian cancer is
still controversial.
In addition, a number of investigators have examined
the utility of novel serum protein biomarkers for early
diagnosis, including the Early Detection Research Net-
work (EDRN), an initiative of the National Cancer Insti-
tute. EDRN evaluated 49 candidate biomarkers for their
suitability for early ovarian cancer detection in blood [4].
These data have shown that none of these serum tests
or combinations have the necessary sensitivity and speci-
ficity to be used as screening tools.
More recently, it has been speculated that cell-free
DNA could be an effective tumor marker that is charac-
terized by high specificity [5]. We have recently explored
the use of circulating tumor DNA for cancer diagnostics
[6]. In short, it appears that circulating tumor DNA is a
promising new biomarker for disease monitoring and for
the selection of personalized therapy. For the most de-
manding application of cancer screening, this method-
ology could be problematic for the following reasons:
1. At early disease stages, the presence of tumor DNA
in the circulation is questionable. Even if very small
amounts exist, sampling on small volumes (such as
10 mL of blood) may not lead to tumor DNA
retrieval, and the test will be falsely negative.
2. It is technically difficult to detect tumor DNA
alternations (mutations, copy number variations
(CNVs), etc.) in the presence of large amounts of non-
tumor DNA, and specific techniques are required [5].
These techniques usually necessitate knowledge of the
mutations to be monitored, which are usually found
by sequencing tumor tissue. Without such knowledge,
the depth of sequencing must be (unattainably) deep
to detect the molecular changes.
Sub-chromosomal changes: novel cancer
biomarker concept
Cohen et al. used a commercially available NIPT method
that identifies fetal aneuploidies by sequencing cell-free
DNA in the maternal plasma. This technology is highly
effective in prenatal screening for detecting fetal aneu-
ploidies of chromosomes 21, 18, 13, X, and Y. This
technique is successful because the amount of fetal
DNA in the maternal circulation is rather high (e.g.,
around 5 % of total DNA). Other authors have previ-
ously shown that the use of NIPT can, in some cases,
detect maternal malignancies at asymptomatic stages
[7, 8]. Using NIPT sequencing data, sub-chromosomal
changes (genomic gains or losses greater than 15
megabases (MB)) were considered by Cohen et al. as
positive indicators of malignancy. In most cases they
were able to map these changes to copy number varia-
tions (CNVs) reported by The Cancer Genome Atlas
Research Network for ovarian cancer [9]. The NIPT se-
quence data were also interpreted using the routine
NIPT pipeline for fetal aneuploidies.
Cohen et al. report that the routine NIPT interpret-
ative algorithm for fetal aneuploidies was not sensitive in
detecting cancers. However, the open source algorithm
used to identify genomic gains or losses greater than
15 MB had 40 % sensitivity for identifying ovarian can-
cer, with approximately the same frequency for early
(6/16) and advanced (7/16) ovarian carcinomas. At this
40 % sensitivity, the specificity was 94 % (2/32). The 12
out of 13 sub-chromosomal changes identified by this
technology represented recurrent changes reported
previously for high-grade serous ovarian carcinomas
[9]. The authors conclude that this technology may
have some utility for ovarian cancer screening or diag-
nosis. By refining their bioinformatic algorithm and
using a larger dataset, this approach may lead to in-
creased sensitivity.
A central question to this approach is how much
tumor DNA is present in the plasma of non-pregnant
populations in comparison to non-tumor DNA. If tumor
DNA is much less abundant than non-tumor DNA, then
this method is unlikely to be highly effective in detecting
CNVs specific to tumor DNA. Unfortunately, the identi-
fied CNVs in circulating plasma DNA could not be con-
firmed by analysis of paired tumor DNA, since the latter
was not available for testing. Consequently, we cannot
say with confidence that these CNVs are indeed somatic
genomic changes in tumor DNA, but their mapping to
CNVs reported by The Cancer Genome Atlas is suggest-
ive and the data look promising.
The finding of the authors that early-stage and late-
stage ovarian carcinomas are detected with about the
same frequency (40 %) is rather surprising because other
classical tumor markers and circulating tumor DNA cor-
relate with tumor burden (and disease stage). Usually,
late-stage disease is diagnosed more effectively than
early-stage disease. The authors provide potential expla-
nations for this paradox but this finding needs to be in-
vestigated further.
Besides the sensitivity of this method, the specificity
needs to be carefully examined. The authors state that
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technical issues with archived plasma specimens or the
reference chromosome set may have led to the false posi-
tive results (2/32) in the control cohorts. Future validation
studies by this group should carefully examine the pre-
analytical steps in this approach to evaluate such technical
issues and ensure that a standardized and robust method
is in place before analysis of clinical specimens.
Conclusions
Cohen et al. report a proof-of-concept method describ-
ing early diagnosis of ovarian cancer using sub-
chromosomal changes in plasma DNA, identified with a
routine NIPT platform. It is unclear if these alterations
are present in tumor-derived circulating DNA. The un-
availability of tumor tissue meant that the central hy-
pothesis could not be confirmed or refuted. If clinical
and analytical performance is validated in future studies,
specific clinical niche needs within ovarian cancer pa-
tient management may be fulfilled with this novel ap-
proach. Using an existing clinical platform in a novel
way – that is, using a platform for prenatal testing in
ovarian cancer diagnosis or for monitoring therapeutic
response – is attractive to both clinicians and hospital
administrators. The cost savings of such an approach
would be significant. But a well-designed validation
study needs to be performed to both reduce pre-analytical
bias and examine paired tumor tissue and plasma DNA.
Such an approach may also hold promise for other cancer
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